Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CRCervoMed Inc. logo

CervoMed Inc. (CRVO)

NASDAQ Capital Market · Currency in USD
$2.31 ▲ +0.07 (+3.13%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.24 ▼ -0.07 (-3.03%)
After hours: Oct 23, 7:41 PM ET

Summary

Previous Close
$2.24
Open
$2.24
Day's Range
$2.22 – $2.33
52 Week Range
$2.13 – $10.00
Volume
110,916
Avg. Volume
5,630,027
Market Cap
$34.93M
Beta (5Y Monthly)
-4.30
PE Ratio (TTM)
--
EPS (TTM)
-$2.96
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$7.00

Profile: CervoMed Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
15
CEO
John J. Alam

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.49 · Revenue est. $50.00K
DateEst.Actual
Aug 10, 2026-$0.87-$0.64Beat
May 18, 2026-$0.90-$0.86Beat
Mar 13, 2026-$0.79-$0.88Miss
Nov 7, 2025-$0.68-$0.84Miss
Aug 8, 2025-$0.61-$0.70Miss
May 12, 2025-$0.60-$0.56Beat

Analyst view

Consensus price target
$7.00 ▲ +203.0%
Range $7.00 – $7.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on CRVO and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.